Cue Biopharma Inc Stock
€1.79
Your prediction
Cue Biopharma Inc Stock
Pros and Cons of Cue Biopharma Inc in the next few years
Pros
Cons
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.At first glance, the financial position of Cue Biopharma can seem concerning, with a declining net income and increased expenditure on research and development in the recent years. However, digging deeper, there are some promising signs that potentially point to future profitability.
The most substantial aspect favorable to Cue Biopharma is its liquidity position. A review of Cue Biopharma's balance sheets for the last three consecutive years reveals an increase in their total assets from 99 million USD in 2020 to 91 million USD in 2022. This suggests Cue Biopharma's financials have been successful in terms of maintaining a sound asset base, especially its cash and short-term investments, which forms a significant portion of its current assets.
Moreover, the company has been successful in raising ample capital through the issuance of its common stock, reflected in the cash flow statements. This reveals investor confidence in Cue Biopharma's business model and its future prospects.
Comments
